Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
In the management of locally advanced esophageal squamous cell carcinoma, the outcomes associated with surgical resection, whether conducted alone or supplemented with postoperative adjuvant radiotherapy and chemotherapy, have been suboptimal. Immune checkpoint inhibitors (ICIs) have shown potential in enhancing the immune system's capacity to target and eliminate cancer cells. Evidence suggests that the concurrent administration of JAK inhibitors with ICIs may improve anti-cancer efficacy, increase patient response rates, and prolong progression-free survival compared to ICIs alone. This prospective, exploratory study aims to assess the efficacy of combining camrelizumab, chemotherapy, and Ivarmacitinib in neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma, with the objective of broadening therapeutic options for this malignancy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent wyraził zgodę na udział w badaniu.
- •Pacjent ma od 18 do 75 lat.
- •Rak przełyku został potwierdzony i można go usunąć operacyjnie.
- •Rak przełyku jest w stadium od II do IVA (według najnowszych wytycznych).
- •Pacjent jest w dobrym ogólnym stanie zdrowia (ECOG 0-1).
- •Nie ma przerzutów do innych narządów, a lekarze oceniają, że rak jest do usunięcia.
✗ Disqualifies
- •Pacjent ma poważne problemy z sercem.
- •Pacjent aktualnie przyjmuje leki przeciwwirusowe lub leczy się na wirusowe zapalenie wątroby typu B.
- •Pacjentka jest w ciąży lub karmi piersią.
- •Pacjent miał inny nowotwór w ciągu ostatnich 5 lat.
- •Pacjent ma chorobę autoimmunologiczną lub problemy z odpornością.
- •Wykazano obecność przerzutów do innych narządów.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- October 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China
Trial contact
Zixiang Ｗu, M.D
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.